Convergent evolution of p38/MAPK activation in hormone resistant prostate cancer mediates pro-survival, immune evasive, and metastatic phenotypes

SummaryAdaptation of cancer cells to targeted therapy follows ecological paradigms observed in natural populations that encounter resource depletion and changing environments, including activation of pro-survival mechanisms, migration to new locations, and escape of predation. We identified the p38 MAPK pathway as a common molecular driver of these three responses during the adaptation to hormone therapy resistance in prostate cancer. The p38 pathway is activated in therapy-resistant cells and mechanistically drives these three convergent responses through sustained AR activity, enhanced invasion and metastasis, and immune evasion. Targeting p38 signaling may represent a new therapeutic strategy to treat men with metastatic, hormone therapy-resistant prostate cancer.

Salvage high-dose-rate brachytherapy for local recurrence of prostate cancer

The article describes a successful experience of using high-dose rate brachytherapy (192Ir) in patients with local recurrence of hormone-resistant prostate cancer. High-dose rate brachytherapy allowed to achieve local biochemical control of prostate cancer without toxicity to pelvic organs, thus, maintaining the quality of life.

A biomimetic approach to hormone resistant prostate cancer cell isolation using inactivated Sendai virus (HVJ-E)

A versatile immobilization method of inactivated Sendai virus (HVJ-E) for metastatic prostate cancer cell isolation.